Basket | Login | Register

 
 
 
 

Current projects

Our work

All EU-funded or sponsored projects that Alzheimer Europe is currently involved in are listed here. News about these projects, can be found here.

For information about previous projects, please refer to our Annual Reports, which can be found here.

For information on Alzheimer Europe's own projects (e.g. annual publications), please refer to our annual Work Plan here.

EPAD (2015-2019)

The European Prevention of Alzheimer’s dementia (EPAD) initiative is a collaborative research effort to improve the chance of successfully preventing Alzheimer’s dementia and to better understand early aspects of Alzheimer’s disease before dementia develops. The goal of the initiative is the prevention of dementia in people with evidence of the disease (such as biomarker abnormalities) who still may have little or no complaints or clinical symptoms. EPAD will establish a European-wide cohort of over 6,000 participants, of which 1,500 will be invited to participate in a trial to test new treatments for the prevention of Alzheimer’s dementia. The five year programme is part of the Innovative Medicines Initiative, a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.

www.ep-ad.org

INDUCT (2016-2019)

INDUCT (Interdisciplinary Network for Dementia Utilising Current Technology) is a four year project under the Marie Sklodowska-Curie Actions Programme. The main aim of INDUCT is to develop a premier quality multi-disciplinary, multi-professional and intersectorial education and training research framework for Europe aimed at improving technology and care for people with dementia, and to use the coherent themes and interrelated Early Stage Researchers ESRs within INDUCT to provide the evidence to show how technology can improve the lives of people with dementia.

www.dementiainduct.eu

MinD (2016-2019)

MinD (Designing for People with Dementia) is a four year project under the Marie Sklodowska-Curie Actions Programme. It aims to help people with dementia engage in social contexts to improve psychosocial wellbeing. Design can offer novel ways of complementing existing care approaches to empower people with dementia in everyday social situations. The project partners will use the concept of mindful design to investigate innovative design solutions, in order to enable self-empowerment and confidence building of people living with dementia. There will be two focus areas: a) personal difficulties with social interaction and b) environmental influences on social engagement. In these two contexts, we will study how personal, wearable designs can help mediate perceptions of identity and emotion management; and how environmental aspects can reduce feelings of information overload and instill feelings of self-empowerment and control.

https://designingfordementia.eu

AMYPAD (2016-2021)

The "Amyloid imaging to prevent Alzheimer’s disease" project aims to improve the diagnostic workup of patients suspected to have Alzheimer's disease and their management. The partners aim to improve knowledge of the natural history of AD in a pre-symptomatic stage, in order to better select patients for trials. In addition, they will monitor changes in beta amyloid deposition in the brain, in order to quantify the impact of novel therapies.

www.amypad.eu

DEM 2 - 2nd European Joint Action on Dementia (2016-2019)

The aim of the 2nd European Joint Action on Dementia, known as Dementia Two or DEM 2, is to promote the implementation in EU Member States of coordinated actions to improve the situation of people living with dementia and their carers. These actions were identified by ALCOVE, the first European Joint Action on Alzheimer Cooperative Valuation in Europe, whose partners built a wealth of evidence and knowledge to support Member States in developing their dementia policies and operational capacity. DEM 2 will focus on four key areas for action: diagnosis and post diagnostic support, crisis and care coordination, residential care and dementia-friendly communities.

www.actondementia.eu

MOPEAD (2016-2019)

This 33-month project aims to deliver a step-change in Alzheimer’s disease (AD) patient engagement strategies and a paradigm shift from late-stage diagnosis to early-stage diagnosis. Multiple regional project sites will be established to identify and test models of efficient early identification of mild AD dementia and prodromal AD patients. These models will be compared and contrasted to identify ways to improve early detection and diagnosis of AD. The findings will enable models of patient access to be established and used in the broader AD community. The four patient engagement models which will be tested in five countries (Germany, Netherlands, Slovenia, Spain and Sweden) include assessment based on AD citizen science (online), Open House Initiatives, Primary care and diabetologists’ offices. MOPEAD is mainly sponsored by the European Union’s Horizon 2020 research and innovation programme and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative (IMI) 2 Joint Undertaking.

www.mopead.eu

Socatel (2017-2020)

H2020 project SoCaTel aims to improve the accessibility, responsiveness, efficiency, transparency and transferability of social and care services by developing a multi-stakeholder platform for the co-creation, and later deployment, of long-term care services.

https://www.socatel.eu/

PRODEMOS (2018-2023)

The PRODEMOS (Prevention of Dementia using Mobile phone Applications) kicked off in January 2018 and will run for five years. This project aims to make an evidence-based dementia prevention strategy using mobile Health accessible to those at increased risk of dementia who are usually not reached by preventive medicine. From a global perspective, the project will target socio-economically deprived populations in the EU and a population at risk of dementia in China. The final aim is to implement this flexible, fully adaptable mHealth platform in a culturally appropriate form in a range of health care settings across the globe. The PRODEMOS project is led by Eric Moll van Charante and Edo Richard (Academish Medisch Centrum bij de Universiteit van Amsterdam). It is sponsored by the European Union’s Horizon 2020 research and innovation programme.

www.prodemos-project.eu/

PARADIGM (2018-2020)

PARADIGM - Patients Active in Research and Dialogues for an Improved Generation of Medicines - is an IMI-funded European project with a mission to provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the “return on the engagement” for all players. The objective is to develop much needed processes and tools for three key decision-making points: research priority setting, design of clinical trials and early dialogue. Building on advances at international level, PARADIGM will integrate the needs, perspectives and expectations of all actors (including vulnerable populations) involved and will also produce a set of metrics to measure the impact of patient engagement. PARADIGM began on 1 March 2018, for 30 months. Alzheimer Europe is a partner and is involved in all work packages of this project.

http://imi-paradigm.eu/

AD Detect and Prevent (2018-2020)

The Alzheimer’s Disease Detect and Prevent project(ADDP) arrives on the scene at an exciting time for brain health research. In keeping with recent changes in the conceptualisation of and terminology related to Alzheimer’s disease (AD), ADDP is pursuing the ambitious aim of developing a digital tool to improve the detection of AD prior to the possible onset of AD dementia and combining this with programmes for reducing lifestyle risk factors related to developing AD dementia.

The project officially started on 1 November 2018 and is a 2-year project. It has a budget of EUR 3.5 million, distributed across 6 partners, with Danish digital therapeutics company Brain+ leading the consortium.

Alzheimer Europe is a partner in this project and is contributing towards the communication and the involvement activities. The latter, is being accomplished by means of a Patient and Public Involvement (PPI) approach.

https://www.addp.eu/

Virtual Brain Cloud (2018-2022)

The VirtualBrainCloud project will develop and validate a decision support system that provides access to high quality multi-disciplinary data for clinical practice. The result will be a cloud-based brain simulation platform to support personalised diagnostics and treatments for neurodegenerative diseases (NDD). The resulting software is tailored to the individual, and bridges multiple scales to identify key mechanisms that predict NDD progression. The interdisciplinary VirtualBrainCloud consortium will also develop robust solutions for legal and ethical matters by interacting with the HumanBrainProject, Alzheimer Europe and ELIXIR, an organization that manages and safeguards EU research data. The project started in December 2018 and will conclude at the end of 2022.

https://virtualbraincloud-2020.eu

SPAN+: Empowering people with dementia (2018-2022)

Empowerment is important for people with dementia in order to remain engaged with significant others, and to remain involved in society and the decision-making process regarding their care and support. Unfortunately, at present, effective empowerment interventions for people with dementia appear to be scarce, both in the Netherlands and internationally. This Dutch project aims to develop an effective empowerment intervention, which is applicable for people with dementia at home as well as in care homes. Together with input of persons with dementia and carers, the project is looking at the effective and useful elements of existing empowerment interventions and to adapt an existing empowerment intervention for people with young-onset dementia (www.spankrachtbijdementie.nl - only in Dutch), to suit the needs of older people with dementia. They are integrating information from: a European survey, carried out in collaboration with Alzheimer Europe; focus-group meetings with people with dementia, family caregivers and health care professionals; and a literature review on empowerment in people with dementia.  

This study is funded by the programme Memorabel of ZonMw and Deltaplan Dementie of Alzheimer Nederland.

https://www.ukonnetwerk.nl/spanplus/en

NEURONET (2019-2022)

The NEURONET initiative (Efficiently Networking European Neurodegeneration Research) is a three-year coordination and support action that began in March 2019. Its aim is set up an efficient platform to boost synergy and collaboration across the Innovative Medicines Initiative (IMI) projects of the Neurodegenerative Disorders (ND) portfolio, assisting in identifying gaps, multiplying its impact, enhancing its visibility and facilitating dovetailing with related initiatives in Europe and worldwide.

http://www.imi-neuronet.org/

RADAR-AD (2019-2022)

RADAR-AD is a collaborative research initiative that explores the potential of mobile and digital technologies to improve the assessment of Alzheimer’s disease (AD).  The AD terminology in the RADAR-AD project reflects the recent conceptualisation of AD as covering the full spectrum of the disease, including both pre-dementia (preclinical and prodromal AD) and dementia phases (mild to severe AD dementia).

RADAR-AD builds on the knowledge and experience gained in a sister project called RADAR-CNS (Remote Assessment of Disease and Relapse – Central Nervous System), which was launched in 2016 and is exploring remote monitoring in people living with multiple sclerosis, epilepsy and depression.

https://www.radar-ad.org/

MIRIADE (2019 – 2023)

MIRIADE (Multi‐omics Interdisciplinary Research Integration to Address DEmentia diagnosis) is a four years project under the Marie Sklodowska-Curie Actions Programme. The main aim of MIRIADE is to train a new generation of scientists that become experts in effective development of novel biomarkers for dementia. MIRIADE will integrate existing biomarker datasets available within the consortium and form a ‘’dementia disease map’’. The young scientists will develop novel biomarker assays using innovative technologies, and MIRIADE will generate novel innovation insights to generate a blueprint for an efficient biomarker development workflow. MIRIADE thus helps to improve the availability of useful biomarkers in clinical practice. This enables early and specific diagnosis of dementia types. Moreover, these biomarkers will help the development of treatments for dementia.

Start date: 1 November 2019

 

 
 

Last Updated: Monday 25 November 2019

 
 
 

Options